Table 2.
Comparison of disease-related variables between training and validation cohorts.
| Variables | Total (n = 322) | Train (n = 225) | Test (n = 97) | p-value |
|---|---|---|---|---|
| Hb, g/L (median, IQR) | 140.00 (128.00, 150.00) | 141.00 (129.00, 151.00) | 138.00 (125.00, 150.00) | 0.307 |
| Ca, mmol/L (median, IQR) | 2.37 (2.26, 2.46) | 2.38 (2.27, 2.47) | 2.36 (2.24, 2.44) | 0.211 |
| P, mmol/L (median, IQR) | 1.06 (0.93, 1.19) | 1.06 (0.92, 1.20) | 1.05 (0.94, 1.18) | 0.561 |
| SUA, μmol/L (median, IQR) | 357.50 (314.00, 413.70) | 357.00 (316.00, 403.00) | 365.00 (297.00, 424.00) | 0.507 |
| IgG, g/L (median, IQR) | 12.20 (10.50, 14.70) | 12.00 (10.50, 14.80) | 12.50 (10.60, 14.20) | 0.874 |
| IgA, g/L (median, IQR) | 2.90 (2.13, 3.98) | 2.83 (2.14, 3.98) | 2.91 (2.07, 3.97) | 0.721 |
| IgM, g/L (median, IQR) | 0.91 (0.69, 1.27) | 0.90 (0.69, 1.25) | 0.91 (0.68, 1.31) | 0.986 |
| C3, g/L (median, IQR) | 1.01 (0.88, 1.18) | 1.01 (0.88, 1.19) | 1.00 (0.89, 1.16) | 0.607 |
| C4, g/L (median, IQR) | 0.24 (0.21, 0.29) | 0.24 (0.20, 0.28) | 0.25 (0.21, 0.29) | 0.91 |
| CRP, mg/L (median, IQR) | 9.97 (4.14, 24.62) | 9.55 (4.23, 22.20) | 11.00 (3.31, 30.50) | 0.469 |
| ESR, mm/h | 23.00 (9.00, 44.00) | 22.00 (9.00, 43.00) | 25.00 (10.00, 45.00) | 0.557 |
| 25 (OH) D, ng/mL (median, IQR) | 20.96 (16.00, 26.00) | 21.00 (16.00, 26.00) | 20.00 (17.00, 25.00) | 0.742 |
| TC groups, mmol/L, n (%) | 0.408 | |||
| <3.70 | 107 (33.23) | 78 (34.67) | 29 (29.90) | |
| 3.70–4.52 | 109 (33.85) | 71 (31.56) | 38 (39.18) | |
| >4.52 | 106 (32.92) | 76 (33.78) | 30 (30.93) | |
| TC groups, mmol/L, n (%) | 0.217 | |||
| <0.89 | 107 (33.23) | 69 (30.67) | 38 (39.18) | |
| 0.89–1.40 | 109 (33.85) | 76 (33.78) | 33 (34.02) | |
| >1.40 | 106 (32.92) | 80 (35.56) | 26 (26.80) | |
| HLA-B27, n (%) | 0.137 | |||
| Negative | 34 (10.56) | 20 (8.89) | 14 (14.43) | |
| Positive | 288 (89.44) | 205 (91.11) | 83 (85.57) | |
| Sacroiliitis average, n (%) | 0.747 | |||
| 2 | 143 (44.41) | 102 (45.33) | 41 (42.27) | |
| 2.5 | 6 (1.86) | 4 (1.78) | 2 (2.06) | |
| 3 | 76 (23.60) | 49 (21.78) | 27 (27.84) | |
| 3.5 | 15 (4.66) | 12 (5.33) | 3 (3.09) | |
| 4 | 82 (25.47) | 58 (25.78) | 24 (24.74) | |
| Hip involvement, n (%) | 0.245 | |||
| No | 185 (57.45) | 134 (59.56) | 51 (52.58) | |
| Yes | 137 (42.55) | 91 (40.44) | 46 (47.42) | |
| Patients on GC, n (%) | 1 | |||
| No | 311 (96.58) | 217 (96.44) | 94 (96.91) | |
| Yes | 11 (3.42) | 8 (3.56) | 3 (3.09) |
Data are presented as the mean ± standard deviation (SD), median (interquartile range), or number (percentage). Hb, Hemoglobin; SUA, Serum uric acid; Ca, Serum calcium; P, Serum phosphorus; TC, Total cholesterol; TG, Triglycerides; IgG, Immunoglobulin G; IgA, Immunoglobulin A; IgM, Immunoglobulin M; C3, Complement component 3; C4, Complement component 4; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; 25 (OH) D, 25-hydroxyvitamin D.